On Tuesday, Shares of Cellectis SA (ADR) (NASDAQ:CLLS), gained 7.21% to $36.45.
Cellectis, declared that preclinical data on its gene-edited allogeneic CAR T-cells will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will be held from May 29 to June 2, 2015 in Chicago.
Cellectis, a biopharmaceutical company, develops cancer products based on engineered T cells armed with a chimeric antigen receptor for the treatment of liquid and solid tumors. Its lead product candidate, UCART19, is an allogeneic engineered T cell product for the treatment of CD19 expressing hematologic malignancies that developed in chronic lymphocytic leukemia and acute lymphoblastic leukemia indications.
Shares of Sophiris Bio Inc (NASDAQ:SPHS), inclined 4.73% to $ 0.8850, during its last trading session.
Sophiris Bio, declared that the first patients have been dosed in a Phase 2a proof of concept trial of PRX302 as a treatment for localized low to intermediate risk prostate cancer.
“The highly targeted treatment with PRX302, which selectively destroys prostate tissue, makes PRX302 a promising treatment approach for localized prostate cancer,” stated Professor Mark Emberton, Director of the Division of Surgery and Urologist at University College London.
Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases.
At the end of Tuesday’s trade, Shares of Callon Petroleum Company (NYSE:CPE), lost -5.43% to $ 7.84.
Callon Petroleum, stated results of operations for the three month period ended March 31, 2015.
The Company highlighted financial and operating results for the first quarter of 2015:
- Net daily production of 8,567 barrels of oil equivalent per day (“BOE/d”), an enhance of 18% over the fourth quarter of 2014, comprised of 83% oil volume
- Lease operating costs, counting workovers, of $9.03 per barrel of oil equivalent (“BOE”), a decrease of 20% contrast to the fourth quarter of 2014
- Adjusted EBITDA, a non-GAAP financial measure(i), of $26.7 million
- Adjusted income accessible to common shareholders, a non-GAAP financial measure(i), of $0.00 per diluted share based on total average diluted shares outstanding of 57.5 million shares
- Financial flexibility improved by the completion of a common equity offering for $65.6 million in net proceeds and reaffirmation of the $250 million borrowing base under its credit facility
Callon Petroleum Company engages in the exploration, development, acquisition, and production of oil and natural gas properties in the Permian Basin in West Texas.
Finally, Patterson Companies, Inc. (NASDAQ:PDCO), ended its last trade with -1.09% loss, and closed at $47.16.
Patterson Companies, stated that merged sales totaled $1.1 billion in its fiscal fourth quarter ended April 25, 2015; 4.2 percent higher than fiscal 2014. Stated net income totaled $64.5 million, or $0.65 per diluted share, contrast to $55.7 million, or $0.55 per diluted share during the same period last fiscal year. After adjusting for one-time transaction costs related to the pending acquisition of Animal Health International and the potential sale of Patterson Medical, fourth quarter fiscal 2015 earnings per diluted share were $0.68.
Patterson Companies, Inc. distributes dental, veterinary, and rehabilitation supplies. Its Dental Supply segment offers consumable dental supplies, such as X-ray films and solutions; impression and restorative materials; hand instruments; sterilization and infection control products; anesthetics; paper, cotton, and disposable products; toothbrushes; dental accessories; printed office products, office filing supplies, and practice administration systems; and radiography equipment, hand pieces, dental chairs and hand piece control units, diagnostic equipment, sterilizers, dental lights and compressors, chair-side restoration systems, digital imaging products, and inter-oral cameras.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
